🇺🇸 FDA
Pipeline program

Temozolomide SUN 5 mg hard capsules, Temozolomide SUN 250 mg hard capsules, Temozolomide SUN 20 mg hard capsules, DC-VACCINE_IRSTIRCCS, Temozolomide SUN 100 mg hard capsules

IRST191.05

Phase 2 small_molecule active

Quick answer

Temozolomide SUN 5 mg hard capsules, Temozolomide SUN 250 mg hard capsules, Temozolomide SUN 20 mg hard capsules, DC-VACCINE_IRSTIRCCS, Temozolomide SUN 100 mg hard capsules for Glioblastoma is a Phase 2 program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).

Program details

Company
Istituto Gentili S.r.l.
Indication
Glioblastoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials